Zacks: Brokerages Expect Charles River Laboratories Intl. Inc (CRL) to Announce $1.42 EPS

Wall Street analysts expect that Charles River Laboratories Intl. Inc (NYSE:CRL) will post $1.42 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Charles River Laboratories Intl.’s earnings, with the highest EPS estimate coming in at $1.53 and the lowest estimate coming in at $1.38. Charles River Laboratories Intl. posted earnings per share of $1.40 during the same quarter last year, which indicates a positive year-over-year growth rate of 1.4%. The company is expected to issue its next earnings results on Tuesday, February 12th.

On average, analysts expect that Charles River Laboratories Intl. will report full-year earnings of $5.93 per share for the current year, with EPS estimates ranging from $5.91 to $5.95. For the next fiscal year, analysts expect that the firm will post earnings of $6.36 per share, with EPS estimates ranging from $6.20 to $6.46. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 7th. The medical research company reported $1.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.38 by $0.15. The firm had revenue of $585.30 million for the quarter, compared to analyst estimates of $567.58 million. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.08%. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.30 earnings per share.

Several research analysts have issued reports on CRL shares. Robert W. Baird lifted their price target on shares of Charles River Laboratories Intl. from $133.00 to $141.00 and gave the stock an “outperform” rating in a research report on Monday, September 17th. Raymond James raised their price objective on shares of Charles River Laboratories Intl. from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 8th. Credit Suisse Group decreased their price objective on shares of Charles River Laboratories Intl. from $129.00 to $121.00 and set a “neutral” rating for the company in a research note on Tuesday, August 21st. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 28th. Finally, Royal Bank of Canada set a $147.00 price objective on shares of Charles River Laboratories Intl. and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Charles River Laboratories Intl. has an average rating of “Buy” and an average price target of $132.06.

Charles River Laboratories Intl. stock opened at $128.86 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.32 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $6.29 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 1.84 and a beta of 0.74. Charles River Laboratories Intl. has a 1 year low of $96.70 and a 1 year high of $139.72.

In other Charles River Laboratories Intl. news, insider David P. Johst sold 23,356 shares of Charles River Laboratories Intl. stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the completion of the sale, the insider now owns 219,849 shares of the company’s stock, valued at approximately $29,899,464. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Ross Smith sold 1,866 shares of Charles River Laboratories Intl. stock in a transaction on Monday, November 12th. The shares were sold at an average price of $134.49, for a total transaction of $250,958.34. Following the sale, the insider now directly owns 12,341 shares of the company’s stock, valued at approximately $1,659,741.09. The disclosure for this sale can be found here. Insiders sold a total of 28,662 shares of company stock valued at $3,887,543 in the last ninety days. Company insiders own 2.10% of the company’s stock.

Large investors have recently modified their holdings of the business. Rhumbline Advisers boosted its stake in shares of Charles River Laboratories Intl. by 4.7% during the 2nd quarter. Rhumbline Advisers now owns 106,963 shares of the medical research company’s stock valued at $12,008,000 after buying an additional 4,842 shares during the period. Mackay Shields LLC boosted its stake in shares of Charles River Laboratories Intl. by 272.4% during the 2nd quarter. Mackay Shields LLC now owns 46,182 shares of the medical research company’s stock valued at $5,184,000 after buying an additional 33,781 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Charles River Laboratories Intl. during the 2nd quarter valued at $460,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Charles River Laboratories Intl. during the 2nd quarter valued at $212,000. Finally, Cadence Capital Management LLC boosted its stake in shares of Charles River Laboratories Intl. by 7.1% during the 3rd quarter. Cadence Capital Management LLC now owns 13,142 shares of the medical research company’s stock valued at $1,768,000 after buying an additional 873 shares during the period. 96.20% of the stock is owned by institutional investors.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Hedge Funds – Risk or Reward?

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply